The approval of Aβ-clearing antibodies like Leqembi (lecanemab) and Kisunla (donanemab) marked a landmark shift toward disease-modifying therapies in Alzheimer’s,…
BUSINESS
Eisai’s Midterm Strategy Focusing on Neurology, Oncology “Gradually Producing Results”: CEO Naito
Eisai’s strategy focusing on neurology and oncology set in its midterm business plan, dubbed “EWAY 2025” kicked off in April, “is gradually producing results,” stressed CEO Haruo Naito at an earnings briefing on October 31. “Particularly, we see steady progress…
To read the full story
Related Article
- Eisai CEO Sees 4 Global Brands as Drivers through FY2020
November 2, 2017
- Eisai’s BACE Inhibitor Enters PIII, Enrollment Begins in US
November 1, 2016
- Forex Moves Drag Down Eisai’s Half-Year Sales despite Bullish Global Brands
November 1, 2016
- 69.2% Response Rate Seen in Lenvatinib, Pembrolizumab Combination: Eisai
October 13, 2016
- Eisai to Kick Off Global PIII for Lenvatinib as First-Line RCC Therapy
October 3, 2016
BUSINESS
- Kissei Cuts H1 Profit Outlook on Tavneos Approval Revocation Risk
October 29, 2026
- Nxera Licenses Fabry Disease Drug from Idorsia
October 29, 2026
- Novo Nordisk Hints at GLP-1 Supply Restrictions to Curb Inappropriate Use
October 29, 2026
- J-TEC, Maruho to Co-Promote Jacemin from April
October 29, 2026
- KM Biologics to Supply Mpox Vaccine to WHO-Led Vaccine Stockpile
October 29, 2026
PHARMA JAPAN welcomes JETRO New York’s Shunsuke Tani as a guest columnist. In occasional contributions, Tani will share his perspectives on US pharmaceutical policy, industry developments, and life in America, drawing on his firsthand experience in the US.---Hello from New…
Japan should fundamentally overhaul its cost-effectiveness assessment (CEA) scheme while putting a hold on CEA-based price adjustments, a new ruling…
Japanese Prime Minister Sanae Takaichi said on October 14 that the government will consider the necessary measures for the FY2027…
Eli Lilly’s breast cancer drug Imulrio (imlunestrant) is finally joining Japan’s NHI price list on October 14, nearly 300 days…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…